Abstract-In addition to its role in neurotransmission, embryonic serotonin (5-HT) has been implicated in the regulation of neurodevelopmental processes. For example, we recently showed that a subset of 5-HT1-receptors expressed in the fetal forebrain mediate a serotonergic modulation of thalamocortical axons response to axon guidance cues, both in vitro and in vivo. This influence of 5-HT signaling on fetal brain wiring raised important questions regarding the source of the ligand during pregnancy. Until recently, it was thought that 5-HT sources impacting brain development arose from maternal transport to the fetus, or from raphe neurons in the brainstem of the fetus. Using genetic mouse models, we uncovered previously unknown differences in 5-HT accumulation between the fore-and hindbrain during early and late fetal stages, through an exogenous source of 5-HT. Using additional genetic strategies, a new technology for studying placental biology ex vivo, and direct manipulation of placental neosynthesis, we investigated the nature of this exogenous source and uncovered a placental 5-HT synthetic pathway from a maternal tryptophan precursor, in both mice and humans. These results implicate a new, direct role for placental metabolic pathways in modulating fetal brain development and suggest an important role for maternal-placentalfetal interactions and 5-HT in the fetal programming of adult mental disorders.
Accumulating evidence suggest that serotonin (5-HT) contributes to the developmental programming of childhoodand adult-onset mental illnesses. This is thought to occur through the capacity of 5-HT to modulate developmental processes such as cell proliferation, migration, and circuit wiring. For instance, genetic studies in mice show that disruption of 5-HT signaling during a restricted period of pre-and postnatal development results in long-term behavioral abnormalities such as increased anxiety in adulthood (Gaspar et al., 2003; Oberlander et al., 2009 ). The developmental programming of adult anxiety can be triggered either by a transient knockdown of a single 5-HT receptor [5-HT1A, (Gross et al., 2002) ] or by a transient developmental exposure to specific serotonin reuptake inhibitors (SSRIs) (Ansorge et al., 2004 (Ansorge et al., , 2008 . The recent discovery of a role for 5-HT in fetal forebrain wiring in utero (Bonnin et al., 2007 (Bonnin et al., , 2011 suggests a potential mechanism by which 5-HT signaling disruption can have longterm consequences on brain function. 5-HT signaling through two receptors (htr1b/1d; 5-HT1B/1D) switches the response of thalamic axons to netrin-1 from attraction to repulsion in vitro (Bonnin et al., 2007) . Targeted disruption in vivo of 5-HT1B/1D receptors expression in the dorsal thalamus led to abnormal thalamocortical axons (TCAs) pathways in the internal capsule and cortex (Bonnin et al., 2007) . Thus, the level 5-HT signaling through the number and/or type of 5-HT receptors activated is critical for normal brain development. The concentration of 5-HT available for receptors activation is likely another important parameter for normal brain development. We recently demonstrated that the fetal forebrain selectively accumulates placenta-derived 5-HT during the initial axon growth period (Bonnin et al., 2011) . These data suggest that certain developing circuits in the fetal brain are sensitive to placental 5-HT during their initial ontogeny, which could be impacted by both genetic and environmental disturbances that are known to increase risk for mental illnesses. The role of 5-HT signaling in fetal brain wiring and the potential importance of placental metabolism in 5-HT-mediated fetal programming are discussed below.
2001). These neurons differentiate in the fetal dorsal raphe (DR) as early as embryonic day (E) 10.5 in the mouse and send axons through the ventral forebrain via the medial forebrain bundle; by E14.5 some 5-HT axons are already reaching rostral regions, including the neocortex (Lidov and Molliver, 1982; Aitken and Törk, 1988) . Since these early studies, 5-HT signaling has been shown to influence diverse processes of brain development such as cell migration, proliferation, maturation, and axon growth [see (Lauder and Krebs, 1978; Rakic and Lidow, 1995; Gaspar et al., 2003; Vitalis and Parnavelas, 2003; Janusonis et al., 2004) ]. Although the actual release of 5-HT synthesized by growing DR axons during early fetal period was never clearly demonstrated, it is assumed that they provide 5-HT to the fetal forebrain and serve its ontogenic roles. Regardless of the actual source of the ligand, the ontogenic effects of 5-HT depend on where and when its receptors are expressed.
A precise, systematic, spatiotemporal expression map of all 5-HT receptors would help understanding and proposing new hypotheses regarding 5-HT signaling role in fetal brain development. There are expression data of varying detail for some 5-HT receptors, either in mice or rats [see (Bonnin et al., 2006) and references therein], but the large number of receptor subtypes [Ͼ15 unique receptor genes, not including splice and editing variants, (Hannon and Hoyer, 2008) ] has made systematic mapping challenging. We started to address this question by obtaining spatial and temporal expression mapping of all Gi/ocoupled 5-HT1 subfamily receptor transcripts in the mouse fetal forebrain, using in situ hybridization (Bonnin et al., 2006) . These studies revealed complex patterns of 5-HT1 receptor subtype expression in the developing forebrain. Surprisingly, receptor transcripts are expressed in regions such as the dorsal thalamus (DT), hippocampal neuroepithelium or neocortex even before DR serotonergic axons reach the area. We noted that the expression patterns of 5-HT1B and 5-HT1D receptor transcripts in the DT were similar to guidance cue receptors expression [i.e. netrin-1 receptors Unc5c and DCC; (Braisted et al., 2000; Garel and Rubenstein, 2004) ]. This suggested that 5-HT signaling could be important for TCA pathway formation, a major developmental process of the DT at these ages (E12.5 to E16.5). This hypothesis was tested in vitro, and in explant studies we showed that 5-HT signaling influences the netrin-1-mediated guidance of thalamic axons. More specifically, a 5-HT1B/1D-mediated decrease in intracellular cAMP level in DT neurons switches their axons response to netrin-1 from attraction to repulsion (Bonnin et al., 2007) . Using in utero electroporation to knockdown or overexpress 5-HT1B/1D receptors simultaneously and specifically in the DT, we observed that 5-HT signaling is important for mediating the growth trajectory of the TCA pathway. This targeted genetic manipulation allowed us to decrease or increase both receptors expression simultaneously starting at E12.5, without affecting transcript expression in other regions of the developing brain. Changes in the path toward the cortex of axons originating from transfected DT neurons were followed and quantified by co-electroporation with a GFP plasmid and immunolabeling of TCAs with specific markers [Netrin-G1a and L1; (Bonnin et al., 2007) ]. We observed two opposing effects of decreasing or increasing 5-HT signaling in DT neurons in vivo. When 5-HT signaling was decreased by knocking down 5-HT1B/1D receptors expression with siRNAs, TCAs followed a ventrally-shifted, or expanded, path in the internal capsule before entering the cortex. Conversely, when 5-HT signaling was increased by overexpressing the receptors, TCAs followed an abnormally restricted dorsomedial path in the internal capsule (Bonnin et al., 2007) . Based on 5-HT effects in vitro and on netrin-1 expression in this region, we proposed that changing 5-HT signaling in TCAs affects their positioning within netrin-1 gradient in the internal capsule (Bonnin et al., 2007) . Thus altering 5-HT signaling in vivo can modulate the patterning of a major axonal pathway in the fetal brain (Fig. 1) . Previous studies have shown that altered TCA pathway formation in SERT and MAOA serotonin transporter (SERT) and monoamine oxydase A (MAOA) knockout (MAOA Ϫ/Ϫ ) mice, which have excess extracellular cortical 5-HT, was rescued in the double knockout (5-HT1B
Ϫ/Ϫ /MAOA Ϫ/Ϫ ) (Salichon et al., 2001) . This suggested that a precise level of 5-HT1B-mediated signaling is important for TCA pathway formation. Curiously, 5-HT1B Ϫ/Ϫ mice do not exhibit obvious defects of TCA organization; however, based on the embryonic expression patterns we described (Bonnin et al., 2006) , signaling through the 5-HT1D receptor, which presents similar pharmacology and cellular localization to 5-HT1B receptor, may be sufficient for normal TCA pathway formation in either (5-HT1B Ϫ/Ϫ /MAOA Ϫ/Ϫ ) or 5-HT1B Ϫ/Ϫ mice. The overlapping temporal and spatial expression of 5-HT1B and 5-HT1D receptors provided the rationale for our combinatorial disruption of both receptors by in utero electroporation (Bonnin et al., 2007) .
As mentioned above, developmental disruptions of 5-HT signaling in utero can lead to abnormal brain function at adult stages. The results described above suggest that a 5-HT-mediated disruption of fetal brain wiring mechanisms could contribute to these long-term effects. Abnormal 5-HT signaling in the fetal brain could result from altered function or expression of 5-HT receptors, as described above, or from altered availability of the ligand itself, 5-HT. Therefore, determining the specific sources of fetal brain 5-HT in utero, which generally have been attributed to fetal and maternal sources, is crucial to understand how disrupted 5-HT signaling affects brain development and the fetal programming of adult disorders.
SOURCES OF 5-HT IN THE FETAL FOREBRAIN
Over the past 40 years, the field has embraced the concept that there are both fetal and maternal contributions of 5-HT during pregnancy. Serotonergic neurons appear early in the fetal hindbrain and could provide an endogenous source of 5-HT. Sources of 5-HT other than the fetal brain was assumed because of the observations that 5-HT receptors expression in the rostral forebrain, craniofacial, and peripheral regions is evident several days before se-rotonergic axons even reach these regions (Buznikov et al., 2001) . Moreover, an exogenous source of 5-HT was consistent with the finding that in Pet-1 knockout (Pet-1Ϫ/Ϫ) mice, in which 70 -80% of raphe neurons fail to develop 5-HT synthetic capacity, thalamic neurons were nonetheless normally targeted (Bonnin and Levitt, unpublished observation) . Thus, all these data were consistent with the existence of an alternative, exogenous source of 5-HT at early stages of development. There are claims regarding multiple sources of the neurotransmitter during fetal development, including the fetal gut and maternal circulation (Lauder et al., 1981; Yavarone et al., 1993) , prior to blood-brain barrier formation. But a careful examination of the literature indicated to us that the exact source of 5-HT in the early fetal brain was not completely clear. Some studies have suggested that maternal blood 5-HT could be transferred to the fetal circulation after crossing the placenta (Côté et al., 2003 (Côté et al., , 2007 . Yet direct or indirect transfer was never demonstrated.
Given the lack of altered axonal guidance problems in the Pet-1Ϫ/Ϫmouse, and to take advantage of the deficiency of 5-HT levels in the adult brain (Hendricks et al., 2003) , we measured 5-HT concentrations throughout embryogenesis in the Pet-1Ϫ/Ϫ and wild type littermate mice in order to gather direct evidence for source of 5-HT other than the fetal brain. We assayed different brain regions using high-pressure liquid chromatography (HPLC). The results uncovered a biphasic nature of the source of 5-HT specifically in the embryonic forebrain. In the hindbrain, the location of raphe neurons, we observed a consistent, massive reduction in 5-HT in the Pet-1Ϫ/Ϫmouse throughout fetal development. However, at early ages (E10.5 to E15.5) 5-HT levels are normal in the Pet-1Ϫ/Ϫmouse compared to wild type littermates. In contrast, from E16.5 on, 5-HT concentration is significantly decreased in the forebrain of Pet-1Ϫ/Ϫ embryos compared to littermate controls, indicating that forebrain 5-HT becomes exclusively provided by DR serotonergic neurons; this corresponds to the timing of raphe axons reaching the forebrain in large numbers (Bonnin et al., 2011) . The differential accumulation of 5-HT in the forebrain, but not the hindbrain, in the Pet-1Ϫ/Ϫ embryos early in development indicates that there is a striking transition from an early exogenous source to a later endogenous (DR serotonergic neurons) source. This switch during development allows the forebrain during early-and mid-embryogenesis to become dependent progressively on its own production of 5-HT ( Fig. 2A) .
From E10.5-15.5, there is no synthetic capacity of the gut to produce 5-HT (Branchek and Gershon, 1989) . Myenteric plexus neurons express TPH2 and are able to uptake 5-HT at E12.5, and synthesize it at E18 (Rothman and Gershon, 1982; Côté et al., 2007) . However, only enterochromaffin cells, which begin to express TPH1 at later stages (E15.5) (Côté et al., 2007) , are able to provide a significant source of 5-HT for the fetal blood (Chen et al., 2001) . We thus turned to the possibility that maternal 5-HT may be the source that is transferred to the fetal brain. We examined fetal brains of SERT knockout (SERT Ϫ/Ϫ ) dams in which maternal there is no detectable blood and platelets 5-HT (Chen et al., 2001 ). Despite this status of the maternal blood, there was no impact on the concentration of 5-HT in the forebrain of SERT ϩ/Ϫ E12.5 embryos from SERT Ϫ/Ϫ or wild type dams (Bonnin et al., 2011) . These data indicated that in contrast to prevailing dogma in the field, maternal blood 5-HT in the mouse is not the main source of fetal blood and forebrain 5-HT at early stages of development. Similar observations were made with another mouse mutant [the pallid mice- (Li et al., 2004) ], in which normal concentrations of fetal forebrain 5-HT were measured at E12.5, even though the maternal blood contains no 5-HT (Del Angelica and Bonnin, unpublished observation).
One additional source of 5-HT had not been investigated-the placenta. We designed studies to examine the possibility that the precursor and essential amino acid tryptophan, originating from the pregnant dam, is converted to 5-HT in the placenta and delivered to the fetal circulation. Immunocytochemistry, RNAseq, and qRT-PCR confirmed that 5-HT biosynthetic enzymes TPH1 and AADC are expressed in the syncytiotrophoblastic cell layer of the placenta at E10.5-E18.5 (Bonnin et al., 2011) . In vitro placental 5-HT neosynthesis was confirmed biochemically at E10.5, E14.5, and E18.5. This synthetic capacity was also observed in human placental fetal villi at 11 weeks of gestation, suggesting that a placental source of 5-HT is important for human fetal development. In order to prove neosynthesis and transport of placental 5-HT from maternal tryptophan precursor, we developed an ex vivo technology for regulating live placental organ perfusion in the mouse (Bonnin et al., 2011) . Briefly, a mouse placenta is harvested and kept alive in an oxygenated and thermostated organ chamber. On the maternal side of the placenta, the uterine artery is cannulated and connected to a low-flow peristaltic pump; on the fetal side, the umbilical artery and veins are cannulated and connected to independent ultra-low flow peristaltic pumps. These independent perfusions allow recreating artificial maternal and fetal blood circulations in intact, live isolated placentas (Bonnin et al., 2011) . Effects of modifying the molecular composition of the artificial "maternal blood" on 5-HT (or other molecules) release into the fetal blood through the umbilical vein are then quantified overtime. Within minutes after tryptophan injection through the maternal uterine artery, we observed large accumulation of newly synthesized 5-HT that was collected through the umbilical vein, demonstrating that the live placenta is able to convert tryptophan to 5-HT, and releases the neurotransmitter into the fetal circulation. In contrast, less than 1% of 5-HT injected on the maternal side could be transported to the fetal circulation. To establish placental synthetic capacity and transport of 5-HT to the fetus in vivo, we blocked TPH1 enzymatic activity by microinjecting small volumes of the TPH inhibitor p-chlorophenyalanine (PCPA) directly into the labyrinth zone of E14.5 placentas in utero (Bonnin et al., 2011) . This pharmacological manipulation significantly reduced 5-HT levels in the placenta and fetal forebrain but not in the fetal hindbrain. These in vivo and ex vivo experiments demonstrate that an exogenous source of 5-HT produced in the placenta is required to maintain normal levels of forebrain 5-HT during early stages of forebrain development (Fig. 2B) . Because the fetal bloodbrain barrier is not functional at early stages of brain development (Daneman et al., 2010) , we proposed that placental 5-HT could reach TCAs and other axons as they grow and influence their response to guidance cues (Bonnin et al., 2007) . This would be consistent with the diffusion of placenta-derived 5-HT within the fetal brain extracellular matrix, similar to bioactive molecules like growth factors and cytokines (see for instance (Li et al., 2009) ). The extracellular accumulation would be analogous in nature with the adult brain, in which 5-HT released through "volume transmission" from axonal varicosities can have longrange effects (De-Miguel and Trueta, 2005) . Stability of the extracellular 5-HT accumulation might occur because of the requirement for uptake and degradation by cells that express MAOA (e.g. serotonergic DR and noradrenergic LC neurons); this is an unlikely route at early stages (ϽE15.5) of brain development, because serotonergic axons are just starting to reach the forebrain at that age, and they are few in number. Interestingly, SERT is expressed in TCAs (but MAOA is not) (Lebrand et al., 1996) , and therefore growing thalamic axons could provide an additional mechanism by which placental 5-HT is taken up and protected from degradation specifically in the forebrain. However, at these early stages of development (E10 -E16), 5-HT immunoreactivity is not detectable above background in growing TCAs. The possibility that placental 5-HT affects TCA formation remains to be fully demonstrated and the impact of a placental-specific TPH1 gene deletion on fetal forebrain 5-HT levels and TCA pathway formation is currently under investigation.
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Although a direct maternal source of 5-HT may also be provided to the embryo before and during placentation (e.g. before E10.5 in the mouse), and may affect very early events of embryonic development (Côté et al., 2007) , our data collectively provided the first evidence that a maternal precursor metabolized directly by the placenta influences fetal brain development. Because similar synthetic capability were observed in early human placenta, the extent to which there is aplacental 5-HT influence on brain development during human pregnancy is key area for new investigations.
CONCLUSION
The results summarized here provide a mechanism through which alterations of tryptophan metabolic pathways in the placenta can affect placental 5-HT synthesis and fetal forebrain development. We showed that there is a progressive switch from an early dependence on an exogenous (placental) source of 5-HT to a later endogenous brain source. The placental source of 5-HT is provided to the forebrain during developmental periods that include cortical neurogenesis, migration, and initial axon targeting [see (Gaspar et al., 2003) ]. A variety of experiments from others and our laboratories show that that these events can be modulated by 5-HT signaling [for example, (Salichon et al., 2001; Janusonis et al., 2004; Bonnin et al., 2007; Homberg et al., 2010) ]. Our proposed model of a progressive switch from placental to endogenous source of fetal forebrain 5-HT suggests that 5-HTdependent developmental processes may be differentially sensitive to maternal and environmental factors depending on when they occur during pregnancy and also depending on the degree to which they impact placental metabolic pathways. Moreover, because the fetus and placenta are genetically identical, specific contributions of gene mutations and allelic variation to mental illness, which are typically assigned to direct fetal impact, must now be examined in the context of a placental contribution (McKay, 2011) .
Most interestingly, earlier studies showed that chronic mild stress during pregnancy in rats not only increases the fraction of free tryptophan in the maternal blood but also 5-HT concentration in the fetal brain; this gestational stress also led to increased anxiety in the adult offspring (Peters, 1988a (Peters, ,b, 1990 . This work was the first indication that maternal tryptophan blood level may be an important trigger or mediator of the fetal programming of adult brain disorders. The results summarized in this review suggest a potential mechanism by which this maternal tryptophanmediated fetal programming can take place: maternal stress-induced increase in free plasma tryptophan availability could increase its metabolism in the placenta and the delivery of 5-HT to the developing forebrain, thereby affecting developmental processes such as axon pathways formation mentioned above. A complete demonstration that this proposed chain of events does lead to longterm effects on adult offspring brain function is currently under investigation. Because of naturally occurring fluctuations in maternal tryptophan blood level, its placental metabolism is likely tightly regulated in order to prevent random negative fetal programming effects. Future studies will focus on abnormal environmental (e.g. chronic stress) or genetic (e.g. MAOA or SERT polymorphisms) conditions that may affect this placental metabolic regulation and therefore generate 5-HT-mediated negative fetal programming events.
The phase of placental source of 5-HT in the mouse corresponds to the first and early second trimesters in the human, prenatal periods that are associated with greater risk for mental illnesses due to maternal perturbations (Oberlander et al., 2009; Brown and Derkits, 2010) . It will be important to examine fetal and placental tryptophan availability throughout normal and abnormal pregnancies. Studies in human and mice already showed that genetic conditions associated with altered tryptophan metabolism during pregnancy have long-term consequences on the offspring; for example mutations in tryptophan 2,3-dioxygenase degrading enzymes (TDO1/2, which are important for tryptophan metabolism in the placenta (Suzuki et al., 2001) ) affect neurogenesis, produce anxiety-related behavior in mice (Kanai et al., 2009) , and in humans are associated with increased risk for schizophrenia, bipolar disorder, and autism (Nabi et al., 2004; Miller et al., 2009) . Interestingly, allelic variants of the Tph1 gene have been associated with schizophrenia (Zaboli et al., 2006) . Although such association needs to be confirmed, it suggests that TPH1 activity in the placenta (and thus placental release of 5-HT to the fetus) could be an important trigger for fetal programming that may contribute to adult mental disorders such as schizophrenia.
